In a mouse model of HER2/neu-driven breast cancer, the Lm-LLO-CD105A and Lm-LLO-CD105B Lm recombinant vaccines that target endoglin (CD105) expressed in tumor vasculature were able to prevent neovascularization, thereby leading to therapeutic responses against primary and metastatic tumors [22]. Here, ERBB2 is linked to breast carcinoma.